June 6th 2011
Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab
June 5th 2011
Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab
June 2nd 2011
Dana Monroe from San Francisco Oncology Associates Discusses Ipilimumab's Side Effects
An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma
May 23rd 2011
Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process
May 20th 2011
Juanita Madison from Seattle Cancer Care Alliance Describes the Provenge Treatment Process
Suzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish
May 6th 2011
At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge
The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma
May 3rd 2011
As immunotherapy options grow, oncologists will need new frameworks of reference for evaluating whether patients are benefiting from the treatments
May 2nd 2011
Researchers at SFOA have examined the challenges ipilimumab's unique side-effect profile presents to oncology professionals
April 18th 2011
Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on Novel Prostate Cancer Immunotherapies
April 13th 2011
Immunotherapies again made headlines in oncology last month
March 31st 2011
The federal agency that determines Medicare reimbursements this week proposed to fully cover the cost of Provenge
March 29th 2011
Bristol-Myers Squibb plans to start rolling out its newly approved melanoma drug ipilimumab (Yervoy) in the next several weeks
March 25th 2011
James P. Allison has never hesitated to buck the system
March 9th 2011
A recent poll conducted by Britain's Royal Society found that what Britons want most is a vaccine that will prevent cancer.
August 17th 2010
The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.
August 16th 2010
Novel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.
New pancreatic cancer vaccine findings were presented at the 2007 Gastrointestinal Cancers Symposium, held January 19-21 in Orlando, FL.